Outcome after nonmyeloablative stem cell transplantation (SCT) for follicular lymphoma (FL).
| Author . | No. of Patients . | Regimen . | Sibling/Unrelated . | Median Follow-up (months) . | Acute II–IV GVHD (%) . | Chronic GVHD (%) . | Relapse (%) . | PFSc (%) . |
|---|---|---|---|---|---|---|---|---|
| a 38 with FL, 5 small lymphocytic lymphoma, and 2 with marginal zone lymphoma | ||||||||
| b 29 with FL, 9 with CLL, and 3 with lymphomplasmacytoid NHL | ||||||||
| c Including responses post donor lymphocyte infusion after transplantation. | ||||||||
| Abbreviations: FCR, fludarabine, cyclophosphamide, rituximab; F/TBI, fludarabine, low-dose total body irradiation; FM, fludarabine, melphalan; NA, information not available. | ||||||||
| Khouri5 | 47 | FCR | 45/2 | 34 | 11 | 51 | 2 | 85 |
| Maris15 | 45a | F/TBI | 22/23 | 24 | 60 | 51 | 15 | 51 |
| Morris16 | 41b | FM/alemtuzumab | NA | 16 | 15 | 6.8 | 44 | 65 |
| Author . | No. of Patients . | Regimen . | Sibling/Unrelated . | Median Follow-up (months) . | Acute II–IV GVHD (%) . | Chronic GVHD (%) . | Relapse (%) . | PFSc (%) . |
|---|---|---|---|---|---|---|---|---|
| a 38 with FL, 5 small lymphocytic lymphoma, and 2 with marginal zone lymphoma | ||||||||
| b 29 with FL, 9 with CLL, and 3 with lymphomplasmacytoid NHL | ||||||||
| c Including responses post donor lymphocyte infusion after transplantation. | ||||||||
| Abbreviations: FCR, fludarabine, cyclophosphamide, rituximab; F/TBI, fludarabine, low-dose total body irradiation; FM, fludarabine, melphalan; NA, information not available. | ||||||||
| Khouri5 | 47 | FCR | 45/2 | 34 | 11 | 51 | 2 | 85 |
| Maris15 | 45a | F/TBI | 22/23 | 24 | 60 | 51 | 15 | 51 |
| Morris16 | 41b | FM/alemtuzumab | NA | 16 | 15 | 6.8 | 44 | 65 |